keyword
MENU ▼
Read by QxMD icon Read
search

RRMS

keyword
https://www.readbyqxmd.com/read/29331092/deep-grey-matter-volume-loss-drives-disability-worsening-in-multiple-sclerosis
#1
Arman Eshaghi, Ferran Prados, Wallace Brownlee, Daniel R Altmann, Carmen Tur, M Jorge Cardoso, Floriana De Angelis, Steven H van de Pavert, Niamh Cawley, Nicola De Stefano, M Laura Stromillo, Marco Battaglini, Serena Ruggieri, Claudio Gasperini, Massimo Filippi, Maria A Rocca, Alex Rovira, Jaume Sastre-Garriga, Hugo Vrenken, Cyra E Leurs, Joep Killestein, Lukas Pirpamer, Christian Enzinger, Sebastien Ourselin, Claudia A M Gandini Wheeler-Kingshott, Declan Chard, Alan J Thompson, Daniel C Alexander, Frederik Barkhof, Olga Ciccarelli
OBJECTIVE: Grey matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with faster disability accumulation in MS. METHODS: We analysed 3,604 brain high-resolution T1-weighted MRI scans from 1,417 participants: 1,214 MS patients (253 clinically-isolated syndrome[CIS], 708 relapsing-remitting[RRMS], 128 secondary-progressive[SPMS], 125 primary-progressive[PPMS]), over an average follow-up of 2...
January 13, 2018: Annals of Neurology
https://www.readbyqxmd.com/read/29318029/thrombin-generation-correlates-with-disease-duration-in-multiple-sclerosis-ms-novel-insights-into-the-ms-associated-prothrombotic-state
#2
Martin Em Parsons, Karen O'Connell, Seamus Allen, Karl Egan, Paulina B Szklanna, Christopher McGuigan, Fionnuala Ní Áinle, Patricia B Maguire
Background: Thrombin is well recognised for its role in the coagulation cascade but it also plays a role in inflammation, with enhanced thrombin generation observed in several inflammatory disorders. Although patients with multiple sclerosis (MS) have a higher incidence of thrombotic disease, thrombin generation has not been studied to date. Objectives: The aim of this study was to characterise calibrated automated thrombography parameters in patients with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) in comparison to healthy controls (HCs)...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29316271/fingolimod-improved-axonal-and-myelin-integrity-of-white-matter-tracts-associated-with-multiple-sclerosis-related-functional-impairments
#3
Michael Gurevich, Roy Waknin, Evan Stone, Anat Achiron
AIMS: Fingolimod hydrochloride is an effective immunomodulatory drug in improving relapsing-remitting multiple sclerosis (RRMS). However, data on the neuroradiologic effects on white matter (WM) have not been demonstrated. In this study, we aimed elucidating the impact of 1-year fingolimod treatment on WM integrity in patients with RRMS. METHODS: Diffusion tensor imaging (DTI) was applied to assess axonal and myelin integrity in specific WM tracts of patients with RRMS prior to and 1 year postfingolimod treatment (n = 30)...
January 5, 2018: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/29316038/effect-of-dimethyl-fumarate-on-gray-and-white-matter-pathology-in-subjects-with-relapsing-multiple-sclerosis-a-longitudinal-study
#4
Robert Zivadinov, Jesper Hagemeier, Niels Bergsland, Eleonora Tavazzi, Bianca Weinstock-Guttman
BACKGROUND: Dimethyl fumarate (DMF) is an oral treatment for relapsing remitting multiple sclerosis (RRMS) with anti-inflammatory and possible neuroprotective properties. Its effect on white matter (WM) and gray matter (GM) pathology is still not fully understood. OBJECTIVE: To characterize the effect of DMF on normal appearing WM (NAWM) and thalamic pathology longitudinally. METHODS: In this observational, longitudinal, 24-month MRI study, 75 RRMS treated with DMF and 40 age- and sex- matched healthy individuals (HIs) were enrolled...
January 5, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29309484/comparative-effectiveness-of-rituximab-and-other-initial-treatment-choices-for-multiple-sclerosis
#5
Mathias Granqvist, Malin Boremalm, Amyar Poorghobad, Anders Svenningsson, Jonatan Salzer, Thomas Frisell, Fredrik Piehl
Importance: Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. Objective: To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. Design, Setting, and Patients: This retrospective cohort study used prospectively collected data to examine specialized care of 2 Swedish county-based community samples of patients with RRMS...
January 8, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29306401/effects-of-lipoic-acid-on-migration-of-human-b-cells-and-monocyte-enriched-peripheral-blood-mononuclear-cells-in-relapsing-remitting-multiple-sclerosis
#6
Joshua D George, Edward Kim, Rebecca Spain, Dennis Bourdette, Sonemany Salinthone
Multiple sclerosis (MS) is a disease of the central nervous system characterized by inflammation and demyelination resulting in clinical disability. The rodent MS model suggests that infiltration of monocytes and B cells contributes to disease pathogenesis. Here, we compared the migratory capacity of human monocytes and B cells from healthy control (HC) and relapsing-remitting MS (RRMS) subjects, with or without lipoic acid (LA) treatment. Basal migration of monocyte-enriched PBMCs from RRMS subjects is significantly higher than HC PBMCs...
February 15, 2018: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/29299614/cortical-and-subcortical-morphometric-and-iron-changes-in-relapsing-remitting-multiple-sclerosis-and-their-association-with-white-matter-t2%C3%A2-lesion-load-a%C3%A2-3-tesla-magnetic-resonance-imaging-study
#7
Ali Al-Radaideh, Imad Athamneh, Hadeel Alabadi, Majed Hbahbih
INTRODUCTION: This study was carried out to investigate the global and regional morphometric and iron changes in grey matter (GM) of multiple sclerosis (MS) patients and link them to the white matter (WM) lesions in a multimodal magnetic resonance imaging approach. MATERIAL AND METHODS: The study involved 30 relapsing-remitting MS (RRMS) patients along with 30 age-matched healthy controls (HC) who were scanned on a 3T Siemens Trio system. The scanning protocol included a 3D, high resolution T1, T2, and T2*-weighted sequences...
January 3, 2018: Clinical Neuroradiology
https://www.readbyqxmd.com/read/29297273/circulating-levels-of-interleukin-17a-tumor-necrosis-factor-alpha-interleukin-18-interleukin-10-and-cognitive-performance-of-patients-with-relapsing-remitting-multiple-sclerosis
#8
Anastasiya G Trenova, Georgi S Slavov, Milena N Draganova-Filipova, Nonka G Mateva, Mariya G Manova, Lyuba D Miteva, Spaska A Stanilova
Multiple sclerosis (MS) is associated with cytokine imbalance and high rate (40-70%) of cognitive impairment. The objective of this study is to investigate the relationship between serum concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-17A, IL-18, IL-10, and cognitive performance in patients with relapsing-remitting MS (RRMS). Methods The study comprised 159 patients with RRMS (mean age 40.08 ± 8.48 years) in remission phase and 86 age-, gender-, and education-matched healthy controls...
January 3, 2018: Neurological Research
https://www.readbyqxmd.com/read/29296636/characterization-of-lymphopenia-in-patients-with-ms-treated-with-dimethyl-fumarate-and-fingolimod
#9
Maryam Nakhaei-Nejad, David Barilla, Chieh-Hsin Lee, Gregg Blevins, Fabrizio Giuliani
Objective: Lymphopenia is a common occurrence of disease-modifying therapies (DMTs) for relapsing-remitting MS (RRMS). The aim of this study was to dissect the prevalence of various lymphocyte subsets in patients with RRMS treated with 2 DMTs commonly associated with lymphopenia, dimethyl fumarate (DMF), and fingolimod (FTY). Methods: Multicolor flow cytometry and multiplex assays were used to identify up to 50 lymphocyte subpopulations and to examine the expression of multiple cytokines in selected patients...
March 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29296635/proinflammatory-b-cell-profile-in-the-early-phases-of-ms-predicts-an-active-disease
#10
Thomas Guerrier, Myriam Labalette, David Launay, Catalina Lee-Chang, Olivier Outteryck, Guillaume Lefèvre, Patrick Vermersch, Sylvain Dubucquoi, Hélène Zéphir
Objective: To assess whether any alteration of B-cell subset distribution and/or the cytokine production capacities of B cells could be associated with any stage of MS and could be predictive of MS evolution. Methods: We prospectively enrolled radiologically isolated syndrome (RIS), clinically isolated syndrome (CIS), naive patients with relapsing remitting MS (RRMS) of any disease modifying drug, and healthy controls (HCs). Peripheral blood B-cell subset distributions and the interleukin (IL)-6/IL-10-producing B-cell ratio were assessed by flow cytometry to evaluate their proinflammatory and anti-inflammatory functional properties...
March 2018: Neurology® Neuroimmunology & Neuroinflammation
https://www.readbyqxmd.com/read/29290973/human-oncoprotein-musashi-2-n-terminal-rna-recognition-motif-backbone-assignment-and-identification-of-rna-binding-pocket
#11
Lan Lan, Minli Xing, Justin T Douglas, Philip Gao, Robert P Hanzlik, Liang Xu
RNA-binding protein Musashi-2 (MSI2) is a key regulator in stem cells, it is over-expressed in a variety of cancers and its higher expression is associated with poor prognosis. Like Musashi-1, it contains two N-terminal RRMs (RNA-recognition Motifs, also called RBDs (RNA-binding Domains)), RRM1 and RRM2, which mediate the binding to their target mRNAs. Previous studies have obtained the three-dimensional structures of the RBDs of Musashi-1 and the RBD1:RNA complex. Here we show the binding of MSI2-RRM1 to a 15nt Numb RNA in Fluorescence Polarization assay and time resolved Fluorescence Resonance Energy Transfer assay...
December 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/29285814/altered-motor-plasticity-in-an-acute-relapse-of-multiple-sclerosis
#12
Isabelle Wirsching, Mathias Buttmann, Thorsten Odorfer, Jens Volkmann, Joseph Classen, Daniel Zeller
In relapsing-remitting MS (RRMS) the symptoms of a clinical relapse subside over time. Neuroplasticity is believed to play an important compensatory role. In this study we assessed excitability-decreasing plasticity during an acute relapse of MS and 12 weeks afterwards. Motor plasticity was examined in 19 patients with clinically isolated syndrome or RRMS during a steroid-treated relapse (t1) and 12 weeks afterwards (t2) using paired-associative stimulation (PAS10). This method combines repetitive electric nerve stimulation with transcranial magnetic stimulation of the contralateral motor cortex to model long-term synaptic depression in the human cortex...
December 29, 2017: European Journal of Neuroscience
https://www.readbyqxmd.com/read/29285552/focal-cortical-thinning-in-patients-with-stable-relapsing-remitting-multiple-sclerosis-cross-sectional-based-novel-estimation-of-gray-matter-kinetics
#13
Lior Orbach, Shay Menascu, Chen Hoffmann, Shmuel Miron, Anat Achiron
PURPOSE: The aim of our study is to identify radiological patterns of cortical gray matter atrophy (CGMA) that correlate with disease duration in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: RRMS patients were randomly selected from the Sheba Multiple Sclerosis (MS) center computerized data registry based on stratification of disease duration up to 10 years. Patients were scanned by 3.0 T (Signa, GE) MRI, using a T1 weighted 3D high resolution, FSPGR, MS protocol...
February 2018: Neuroradiology
https://www.readbyqxmd.com/read/29279008/comparative-analysis-of-thermal-unfolding-simulations-of-rna-recognition-motifs-rrms-of-tar-dna-binding-protein-43-tdp-43
#14
Amresh Prakash, Vijay Kumar, Naveen Kumar Meena, Md Imtaiyaz Hassan, Andrew M Lynn
TAR DNA-binding protein 43 (TDP-43) inclusions have been found in Amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases. Many studies suggest the involvement of RNA recognition motifs (RRMs) in TDP-43 proteinopathy. To elucidate the structural stability and the unfolding dynamics of RRMs, we have carried out atomistic molecular dynamics simulations at two different temperatures (300 K and 500 K). The simulations results indicate that there are distinct structural differences in the unfolding pathway between the two domains and RRM1 unfolds faster than RRM2 in accordance with the lower thermal stability found experimentally...
December 26, 2017: Journal of Biomolecular Structure & Dynamics
https://www.readbyqxmd.com/read/29276624/subcutaneous-interferon-%C3%AE-1a-three-times-weekly-and-the-natural-evolution-of-gadolinium-enhancing-lesions-into-chronic-black-holes-in-relapsing-and-progressive-multiple-sclerosis-analysis-of-prisms-and-spectrims-trials
#15
A Traboulsee, Dkb Li, R Tam, G Zhao, A Riddehough, J Fang, F Dangond, L Kappos
Background: Evolution of gadolinium-enhancing lesions into chronic black holes (CBH) may be reduced by interferon (IFN) therapy. Objective: The objective of this paper is to assess the effect of IFN β-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (SPMS). Methods: A post hoc, exploratory analysis of patients with RRMS and SPMS with monthly MRI scans (months -1 to 9) from two separate placebo-controlled clinical trials of IFN β-1a was conducted...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29260023/definition-prevalence-and-predictive-factors-of-benign-multiple-sclerosis
#16
REVIEW
Tatjana Reynders, Miguel D'haeseleer, Jacques De Keyser, Guy Nagels, Marie B D'hooghe
Background: Multiple sclerosis (MS) is characterized by a great inter-individual variability in disease course and severity. Some patients experience a rather mild course, controversially called 'benign MS' (BMS). The usefulness of this entity in clinical practice remains unclear. Methods: We performed a literature search in PubMed, Web of Science and Cochrane Library databases from November 1980 to December 2015, using the following key words: benign multiple sclerosis, diagnosis, imaging, prognosis, predictive, natural history and predefined inclusion criteria...
June 2017: ENeurologicalSci
https://www.readbyqxmd.com/read/29249139/omalizumab-for-refractory-chronic-spontaneous-urticaria-during-concurrent-immunomodulatory-therapy-for-multiple-sclerosis
#17
N Syrigos, D Grapsa, E Syrigou
Data derived from previous clinical trials and real-life studies have shown that omalizumab may represent an effective third-line treatment option for patients with chronic spontaneous urticaria (CSU) refractory to standard antihistamine treatment. Nevertheless, the safety and efficacy of omalizumab treatment for CSU, when administered concurrently with other immunomodulatory agents remains largely unknown. We herein present the case of a female patient with relapsing-remitting multiple sclerosis (RRMS), under treatment with interferon beta-1a, azathioprine and gabapentin, who was successfully treated with omalizumab for refractory CSU...
November 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29248894/a-standardised-frankincense-extract-reduces-disease-activity-in-relapsing-remitting-multiple-sclerosis-the-saba-phase-iia-trial
#18
Klarissa Hanja Stürner, Jan-Patrick Stellmann, Jan Dörr, Friedemann Paul, Tim Friede, Sven Schammler, Stefanie Reinhardt, Susanne Gellissen, Gainet Weissflog, Tobias Djamsched Faizy, Oliver Werz, Sabine Fleischer, Lea A I Vaas, Frank Herrmann, Ole Pless, Roland Martin, Christoph Heesen
OBJECTIVE: To investigate whether oral administration of a standardised frankincense extract (SFE) is safe and reduces disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: We performed an investigator-initiated, bicentric phase IIa, open-label, baseline-to-treatment pilot study with an oral SFE in patients with RRMS (NCT01450124). After a 4-month baseline observation phase, patients were treated for 8 months with an option to extend treatment for up to 36 months...
December 16, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29246870/metabolic-defects-in-multiple-sclerosis
#19
REVIEW
Reginald C Adiele, Chiedukam A Adiele
Brain injuries in multiple sclerosis (MS) involve immunopathological, structural and metabolic defects on myelin sheath, oligodendrocytes (OLs), axons and neurons suggesting that different cellular mechanisms ultimately result in the formation of MS plaques, demyelination, inflammation and brain damage. Bioenergetics, oxygen and ion metabolism dominate the metabolic and biochemical pathways that maintain neuronal viability and impulse transmission which directly or indirectly point to mitochondrial integrity and adenosine triphosphate (ATP) availability indicating the involvement of mitochondria in the pathogenesis of MS...
December 13, 2017: Mitochondrion
https://www.readbyqxmd.com/read/29246612/extracellular-mir-145-mir-223-and-mir-326-expression-signature-allow-for-differential-diagnosis-of-immune-mediated-neuroinflammatory-diseases
#20
Wessam E Sharaf-Eldin, Nirmeen A Kishk, Yehia Z Gad, Heba Hassan, Mohamed A M Ali, Maha S Zaki, Mohamed R Mohamed, Mona L Essawi
BACKGROUND: Although misdiagnosis of neuromyelitis optica spectrum disorder (NMOSD) with neuropsychiatric systemic lupus erythematosus (NPSLE) or multiple sclerosis (MS) is not infrequent, reliable biomarkers remains an unmet need. Extracellular microRNAs (miRNAs) represent a worthy avenue to identify biomarkers for differential diagnosis. We aimed to explore the potential role of some selected circulating miRNAs as biomarkers for the differential diagnosis in immune-mediated neuroinflammatory diseases...
December 15, 2017: Journal of the Neurological Sciences
keyword
keyword
33225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"